

POTENTIAL INTERVENTIONS IN THE MANAGEMENT OF NEUROPATHIC PAIN

Sukhvir kaur¹, A.C Rana¹, Shaveta Gangwani¹, Ramica Sharma¹

¹ Rayat Institute of Pharmacy, SBS Nagar, Ropar-144533, India

*Corresponding Author Email: sukhvirdhanoa88@gmail.com

Review Article

RECEIVED ON 18-08-2011

ACCEPTED ON 31-08-2011

ABSTRACT

Neuropathic pain (NP) is a wide term, associated with damage to peripheral nerves, spinal nerves and to the central nervous system (CNS). It is a leading cause of morbidity and mortality and its prevalence is continuously increasing in industrialised nations. It is characterised by allodynia, hyperalgesia and hyperpathia leading to sympathetic dysfunction and dystrophic changes. Number of synthetic drugs are used in the management of neuropathic pain but are of no use as they elicit several adverse effects. Hence the present review delineated with the management of neuropathic pain by the aid of herbal drugs and few newer synthetic drugs that are efficacious and potent.

KEYWORDS: neuropathic pain, allodynia, hyperalgesia, sympathetic dysfunction

Introduction

Neuropathic pain is defined as dysfunction of peripheral or central nervous system.¹ Nerve damage due to evoke pain results in allodynia (Pain due to stimulus that does not normally provoke pain, it can be provoked by touch stimulation or cooling) and Hyperalgesia (Provoked by heat stimulation).² Various mediators are implicated in the pathogenesis of NP such as neuropeptides,³ neurokinins,⁴ inflammatory mediators,⁵ growth factors and adhesions molecules such as intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM).⁶ Neuropeptides such as cholecystokinin (CCK), Vasointestinal polypeptide (VIP), galanin, and NO (Nitric oxide) and Neurokinins like substance P and calcitonin gene related protein (CGRP) increases during nerve injury.^{7,8} It has been shown that inflammatory mediators such as prostaglandins (PGs) increases level of intracellular cyclic adenosine monophosphate (cAMP) which leads to hyperalgesia by activating protein kinase A (PKA) and calcium (Ca²⁺) channels.⁹ Further, Tumour Necrosis Factor (TNF- α), Interleukins (ILs) present in dorsal horn neurons are also implicated in neuropathic pain. TNF- α has been documented to activate the Tumour necrosis factor receptor 1 (TNFR1) and TNFR2 receptors, that are upregulated during inflammation,⁵

Moreover activation of TNFR1 and TNFR2 are reported to activate tetrodotoxin-resistant (TTX-R) sodium channels via the p38 mitogen activated protein kinase (MAPK) system and increases membrane potassium (K⁺) ion conductance in a non-voltage-gated fashion across the membrane leading to overall neuronal hyper-excitability and hence leading to NP.¹⁰ IL-1 α and IL-1 β bind to the IL-1 receptor type I that in turn activates tyrosine kinases (TKs) and protein kinase C (PKC) that has been implicated in the progression of NP.^{11,12} Moreover, in NP there is excessive formation of reactive oxygen species (ROS).¹³ ROS has been shown to enhance the effects of other inflammatory mediators including bradykinin and Prostaglandin E2 (PGE₂).¹⁴

Nerve injury induces pain sensitization either by central or peripheral mechanisms.¹⁵ After nerve injury, there is expression of abnormal sodium channels in peripheral nerves. These changes are likely to be key factors in the pathogenesis of both spontaneous and evoked ectopic discharge in damaged and undamaged primary afferent neurons. Changes in sodium channel expression in CNS neurons leads to altered states of neuronal excitability and produce pathologic changes in the process that regulates

neurotransmitter release.¹⁶ Various evidences too indicates that in NP there is activation of microglial and astrocytes that in return activates p³⁸ MAPK including extracellular regulating kinase (ERK).¹⁷ Excitatory neurotransmitters like glutamate, aspartate also play a vital role in pathogenesis of NP. Glutamate has been found to stimulate N-methyl-D-aspartate (NMDA) receptors, which further elevates calcium levels and causes release of various neurotransmitters and neuromodulators like brain derived neurotrophic factor (BDNF), PGE₂, IL-6.¹⁸ Further PGE₂ mediate the release of excitatory amino acids (EAA), Substance P (SP), Calcitonin gene related protein (CGRP), and NO that are responsible for generation of NP.¹⁹ Moreover, IL-6 by binding to IL-6 receptors (IL-6R) causes sensitisation in NP.²⁰

Thus, by knowing various signalling mechanisms responsible in the progression of NP, various new safer, efficacious therapeutic interventions can be designed. Hence, the review deals with management of NP via herbal drugs and few synthetic drugs.

Management of Neuropathic Pain

Pharmacological interventions

ANTIPILEPTICS:

Antiepileptic drugs are the best option in the management of NP as both possess similar pathophysiology.²¹ Central sensitization and ectopic neuronal firing are common in epilepsy²² and NP²³ as both the disorders are associated with central nervous system injury. Newer antiepileptics like Lamotrigine, Gabapentin, are widely used in the treatment of NP by causing blockade of sodium channels and calcium channels.²⁴ Further, Topiramate is reported to relieve NP by enhancing the GABAergic transmission and by inhibition of

glutamatergic transmission.²⁵ Moreover, antiepileptic drugs such as zonisamide possess free radical scavenging property and reduces symptoms associated with NP.²⁶

ANTIDEPRESSANTS

Antidepressants are commonly prescribed for NP.²⁷ Antidepressants have been reported to affect multiple neurotransmitter receptors and ion channels implicated in NP such as NMDA receptors and opioid receptors.²⁸ It has been well known that antidepressants have inhibitory effects on 5-hydroxytryptamine (5-HT) and noradrenaline (NA), which have been shown to modulate NP.²⁹ Tricyclic antidepressants (TCA) such as amitriptyline, nortriptyline, desipramine and certain novel antidepressants such as bupropion, venlafaxine, duloxetine are effective in the treatment of NP.³⁰ Tricyclic antidepressants in addition to blocking serotonin (5-HT) and norepinephrine (NE) reuptake are relatively potent sodium channel blockers.³¹ Selective serotonin reuptake inhibitors such as Trazodone, Nefazodone, Venlafaxine act by blocking 5-HT reuptake pump, and by down regulation of 5-HT autoreceptors.³²

OPIOIDS

Opioids have been reported to block A delta fiber and C fiber mediated NP.³³ Moreover, corticosteroids are widely accepted as analgesic in NP as they block the potassium-evoked release of SP. Strong opioids such as morphine, hydromorphone, fentanyl, levorphanol, oxycodone, and methadone are the common opioids used in treatment of NP.³⁴ Methadone binds to the NMDA receptor, a known modulator of NP and also inhibits the reuptake of norepinephrine and serotonin.³⁵ **Table 1** indicates synthetic analogues used in management of NP with mechanism of action.

Category	Drugs	Mechanism of action	Adverse effects
Antiepileptics	Lamotrigine/, Gabapentin	Blockade of sodium and calcium channels	Blurred vision, ataxia, pruritis, somnolence, peripheral edema, anorexia, agitation & irritability
	Zonisamide	Free radical scavenging property	
Antidepressants	Trazodone, Nefazodone, Venlafaxine	Blockade of serotonin (5-HT) reuptake pump, Down regulation of 5HT _{1A} autoreceptors, Down regulation of postsynaptic 5-HT _{2A} receptors	Constipation, ataxia, dry mouth, insomnia, seizures, dizziness, hot flashes, urinary retention, weight gain, arrhythmia.
Opioids	Morphine, Hydromorphone, Fentanyl, Levorphanol, Oxycodone, Methadone	NMDA receptor antagonist and inhibits the reuptake of norepinephrine and serotonin	Drowsiness, sedation, constipation, dizziness, nausea/vomiting

Table 1: Shows various synthetic drugs with their mechanism in the management of NP

Drug	Mechanism of action
Ginkgo biloba	Blocks induction of inducible nitric oxide synthase (iNOS) and release of nitric oxide (NO)
Panax ginseng	Inhibit the voltage-gated Na ⁺ channels
Ocimum sanctum	Decreases the oxidative stress and calcium levels
Acorus calamus	Decreases the oxidative stress and calcium levels
Emblica officinalis	Inhibits lipid peroxidation and restore antioxidant enzymes
Combination of Psidium guajava, Momordica charantia and Coccinia indica	Inhibits protein kinase C and act as antioxidant

Table 2 Shows Herbal drugs in the management of neuropathic pain

HERBAL DRUGS

Ginkgo biloba

Ginkgo is the dried leaves of *Ginkgo biloba* Linn., the only member of family Ginkgoaceae. It has been well reported that *Ginkgo biloba* extract shows anti-inflammatory and analgesic effects in formalin induced acute inflammatory pain model.³⁶ *Ginkgo biloba* has also been shown to decrease thermal hyperalgesia in a carrageenan induced inflammatory pain model.³⁷ The beneficial effect of *Ginkgo biloba* extract in NP is mainly due to a combination of an antioxidant, anti-inflammatory and a platelet activating factor antagonist effect and a protective effect against NMDA induced neurotoxicity.³⁸ *Ginkgo biloba* act by blocking induction of inducible nitric oxide synthase (iNOS) and release of nitric oxide (NO), which is known to play a significant role in nociceptive processing in the spinal cord.³⁹ Extracts of *Ginkgo biloba* contain two main groups of active constituents: ginkgo flavone glycosides (flavanoids) and terpenes lactones.³⁸ Oral administration of the flavanoid, quercetin, was reported to reverse thermal hyperalgesia in a mouse model of diabetic neuropathy.⁴⁰

Panax ginseng

Ginseng is the dried root of various species of *Panax*, like *P.ginseng* (Korean ginseng), *P.japonica* (Japanese ginseng), *P. Notoginseng* (Chinese ginseng) and *P.quinquefolium* (American ginseng), belonging to family Araliaceae. A polyacetylenic compound, (9R, 10S)-epoxyheptadecan-4,6-diyne-3-one (EHD), isolated from ginseng extract has been reported to inhibit the voltage-gated Na^+ channels in primary sensory neurons which has been implicated in the pathogenesis of NP perception, thus helpful in relieving neuropathic pain.⁴¹

Ocimum sanctum

Ocimum sanctum belonging to family Labiatae, also known as 'Holy Basil' is known for its therapeutic potentials. It has been demonstrated to block the NP by decreasing

the oxidative stress and calcium levels, which play important role in pathogenesis of NP.⁴² Saponins, important constituent in *Ocimum sanctum* is believed to be responsible for its beneficial effect in NP.⁴³ *Ocimum sanctum* is known to exert various other effects such as antidiabetic, antiulcer and antimicrobial.⁴⁴

Acorus calamus

Acorus calamus belonging to family Araceae is an indigenous plant, used in the management of severe inflammatory disorders. *Acorus calamus* prevented chronic constriction injury (CCI) induced neuropathy which may be attributed to its multiple actions including anti-oxidative, anti-inflammatory, neuroprotective and calcium inhibitory actions.⁴⁵

Emblica officinalis

Emblica officinalis (Amla) is a tropical, deciduous, small to medium sized tree with pale yellowish fleshy globose fruits. *E. officinalis* is famously known for its hepatoprotective and antioxidant activities.⁴⁶ The effective components in *E.officinalis* are flavanoids, tannins, Vitamin-C and are antioxidant in action.⁴⁷ Quercetin, a bioflavonoid is reported to attenuate neuropathic symptoms by inhibition of lipid peroxidation and restoration of antioxidant enzymes.⁴⁸

Psidium guajava, Momordica charantia and Coccinia indica

P. guajava, commonly known as Guava is a native plant in tropical America and South East Asia. *M. charantia*, commonly referred to as bitter melon or Korolla, is a climbing plant, cultivated throughout Southern Asia. *C. indica*, commonly known as Telakucha is a climbing plant, cultivated throughout Southern Asia. It has been reported that the combination of *P. guajava*, *M. charantia* and *C. Indica* attenuated neuropathic pain symptoms by inhibiting protein kinase C and oxidative stress.⁴⁹ **Table 2** indicates herbal drugs used in management of NP with mechanism of action.

Conclusion:

The present review opens vista for the management of neuropathic pain via herbal drugs and few synthetic drugs.

Acknowledgement:

I express my thanks to Rayat and Bahra group and to the Chairman of the college S. Gurvinder Singh Bahra and S. Nirmal Singh Rayat for providing supportive and friendly atmosphere and excellent facilities in and around the region.

References:

1. Saxena AK, Azad R, Advances in the Mechanism, Diagnosis and Management of Neuropathic pain: Current opinions And Perspectives. Indian Journal of Anaesthesia, 50:249-257, (2006).
2. Beggs S, Salter W, Neuropathic Pain: Symptoms, Models, and Mechanisms. Drug Development Research, 67:287-301, (2006).
3. Nee RJ, Butler D, Management of peripheral neuropathic pain: Integrating neurobiology, neurodynamics, and clinical evidence. Physical Therapy in Sport, 36-49, (2006).
4. Juliano F, Beirith AA, Mori MAS, Araujo RC, Bader M, Pesquero JB, Calixto JB, Reduced Nerve Injury-Induced Neuropathic Pain in Kinin B₁ Receptor Knock-Out Mice. Journal of Neuroscience, 25:2405-2412, (2005)
5. Leung L, Cahill CM, TNF- α and neuropathic pain - a review. Journal of Neuroinflammation, 7:27, (2010).
6. Ricardo V, Tilley D, Vogel L, Benyamin R. The Role of Glia and the Immune System in the Development and Maintenance of Neuropathic Pain. Pain Practice, 10:167-184, (2010).
7. Hökfelt T, Zhang X, Hallin WZ, Messenger plasticity in primary sensory neurons following axotomy and its functional implications. Trends Neuroscience, 17:22-30, (1994).
8. Noguchi K, Dubner R, DeLeon M, Semba E, Ruda M, Axotomy Induced Preprotachykinin Gene Expression in a Subpopulation of Dorsal Root Ganglion Neurons. Journal of Neuroscience Research, 37:596-603, (1994).
9. Fischer MJM, Mak SWY, McNaughton PA, Sensitisation of Nociceptors – What are Ion Channels Doing?. The Open Pain Journal, 3:82-96, (2010).
10. Jin X, Gereau R, Wt: Acute p38-mediated modulation of tetrodotoxin resistant sodium channels in mouse sensory neurons by tumor necrosis factor- α . Journal of Neuroscience, 26:246-255, (2006).

11. Kulmatycki KM, Jamali F, Drug Disease Interactions: Role of Inflammatory Mediators in Pain and Variability in Analgesic Drug Response. Journal of Pharmacy and Pharmaceutical Sciences, 10:554-566, (2007).
12. Oliveira CMB, Sakata RK, Issy AM, Gerola LR, Salomão R, Cytokines and Pain. Revista brasileira de anesthesiologia, 61: 255-265, (2011).
13. Kim D, You B, Jo EK, Han SK, Simon MI, Lee SJ, NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proceedings of the National Academy of Sciences, 1-6, (2010).
14. Dray A, Inflammatory mediators of pain. British journal of Anaesthesia, 75:125-131, (1995).
15. Ji RR, Wen YR, Neural-Glial Interaction in the Spinal Cord for the Development and Maintenance of Nerve Injury-Induced Neuropathic Pain. Drug development research, 67:331-338, (2006).
16. Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, Gold MS, Porreca F, Strichartz GR, The Role of Sodium Channels in Chronic Inflammatory and Neuropathic Pain. The Journal of Pain, 7:S1-S29, (2006).
17. Ji RR, Suter MR, p38 MAPK, microglial signaling, and neuropathic pain. Molecular Pain, 3:33, (2007).
18. Vallejo R, Tilley DM, Vogel L, Benyamin R, The Role of Glia and the Immune System in the Development and Maintenance of Neuropathic Pain. Pain Practice, 10:167-184, (2010).
19. Smith HS, Arachidonic Acid Pathways in Nociception. Journal of supportive oncology, 4:277-287, (2006).
20. Svensson CI, Interleukin-6: a local pain trigger?. Arthritis Research & Therapy, 12:145, (2010).
21. Ruscheweyh R, Sandkühler J, Epileptiform activity in rat spinal dorsal horn in vitro has common features with neuropathic pain. Pain, 105:327-338, (2003).
22. Engelborghs S, D'Hooge R., De Deyn PP, Pathophysiology of epilepsy. Acta Neurologica Belgica, 100:201-213, (2000).
23. Manning DC, New and Emerging Pharmacological Targets for Neuropathic Pain. Current Pain and Headache Reports, 8:192-198, (2004).
24. Pappagallo M, Newer Antiepileptic Drugs: Possible Uses in the Treatment of Neuropathic Pain and Migraine. Clinical Therapeutics, 25:2506-2538, (2003).
25. Landmark CJ, Antiepileptic Drugs in Non-Epilepsy Disorders Relations between Mechanisms of Action and Clinical Efficacy. CNS Drugs, 22:27-47, (2008).
26. Rout SK, Kar DM, a review on antiepileptic agents, current research and future prospectus

- on conventional and traditional drugs. *International Journal of Pharmaceutical Sciences Review and Research*, 3:19-23, (2010).
27. Galluzzi KE, Management of Neuropathic Pain. *The Journal of the American Osteopathic Association*, 105:S12-S19, (2005).
 28. Nagata K, Imai T, Yamashita T, Tsuda M, Saitoh HT, Inoue K, Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. *Molecular Pain*, 5:20, (2009).
 29. Sindrup SH, Otto M, Finnerup NB, Jensen TS, Antidepressants in the Treatment of Neuropathic Pain. *Basic & Clinical Pharmacology & Toxicology*, 96:399-409, (2006).
 30. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede RD, Turk DC, Wallace MS, Pharmacologic management of neuropathic pain: Evidence-based recommendations. *Pain*, 132:2370-251, (2007).
 31. Gilron I, Watson CPN, Cahill CM, Moulin DE, Neuropathic pain: a practical guide for the clinician. *Canadian Medical Association Journal*, 175: 265-275, (2006).
 32. Liu VWC, Lam LW, Chiu HFK, Antidepressants for the Treatment of Neuropathic Pain. *Hong Kong Journal of Psychiatry*, 12:23-27, (2002).
 33. Chen H, Lamer TJ, Rho RH, Marshall KA, Sitzman BT, Ghazi SM, Brewer RP, Contemporary Management of Neuropathic Pain for the Primary Care Physician, *Mayo Clinic Proceedings*, 79:1533-1545, (2004).
 34. Allen S, Pharmacotherapy of neuropathic pain. *Continuing Education in Anaesthesia, Critical Care & Pain*, 5:134-137, (2005).
 35. Foley KM, Opioids and Chronic Neuropathic Pain. *The New England journal of medicine*, 348:1279-1281, (2003).
 36. Abdel-Salam OM, Baiuomy AR, El-batran S, Arbid MS, Evaluation of the anti-inflammatory, antinociceptive and gastric effects of Ginkgo biloba in the rat. *Pharmacological Research*, 49:133-142, (2004).
 37. Biddlestone L, Corbett AD, Dolan S, Oral administration of Ginkgo biloba extract, EGb-761 inhibits thermal hyperalgesia in rodent models of inflammatory and post-surgical pain. *British Journal of pharmacology*, 151:285-289, (2007).
 38. Kim YS, Park HJ, Kim TK, Moon DE, Lee HJ, The Effects of Ginkgo Biloba Extract EGb 761 on Mechanical and Cold Allodynia in a Rat Model of Neuropathic Pain. *Anesthesia and Analgesia*, 108:1958 -1963, (2009).
 39. Wadsworth TL, Koop DR, Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signalling pathways involved in the release of nitric oxide. *Chemico-Biological Interactions*, 137:43-58, (2001).
 40. Anjaneyulu M, Chopra K, Quercetin, a biflavonoid, attenuates thermal hyperalgesia in a mouse model of diabetic neuropathic pain. *Progress in neuro-psychopharmacology and biological psychiatry*, 27:1001-1005, (2003).
 41. Choi SJ, Kim TH, Shin YK, Lee CS, Park M, Lee HS, Song JH, Effects of a polyacetylene from Panax ginseng on Na⁺ currents in rat dorsal root ganglion neurons. *Brain Research*, 1191:75-83, (2008).
 42. Kaur G, Jaggi AS, Singh N, Exploring the potential effect of Ocimum sanctum in vincristine-induced neuropathic pain in rats. *Journal of Brachial Plexus and Peripheral Nerve Injury*, 5:3, (2010).
 43. Yin X, Zhang Y, Wu H, Zhu X, Zheng X, Jiang S, Zhuo H, Shen J, Li L, Qiu J, Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats. *Journal of Pharmacological Sciences*, 95:256-266, (2004).
 44. Modak M, Dixit P, Londhe J, Ghaskadbi S, Devasagayam TPA, Indian Herbs and Herbal Drugs Used for the Treatment of Diabetes. *Journal of Clinical Biochemistry and Nutrition*, 40:163-173, (2007).
 45. Muthuraman A, Singh N, Attenuating effect of Acorus calamus extract in chronic constriction injury induced neuropathic pain in rats: an evidence of anti-oxidative, anti-inflammatory, neuroprotective and calcium inhibitory effects. *BMC Complementary and Alternative Medicine*, 11:24, (2011).
 46. Jose JK, Kuttan R, Antioxidant activity of Emblica officinalis. *Journal of clinical Biochemistry and Nutrition*, 19:63, (1995).
 47. Haque R, Bin-Hafez B, Ahmad I, Parvez S, Pandey S, Raisuddin S, Protective effect of Emblica officinalis Gaertn. in cyclophosphamide-treated mice. *Human and Experimental Toxicology*, 20:643-650, (2001).
 48. Kumar NP, Annamalai AR, Thakur RS, Antinociceptive property of Emblica officinalis Gaertn (Amla) in high fat diet-fed/low dose streptozotocin induced diabetic neuropathy in rats. *Indian journal of experimental biology*, 47:737-742, (2009).
 49. Rafiq K, Sherajee SJ, Nishiyama A, Sufiun MA, Mostofa M, Effects of indigenous medicinal plants of Bangladesh on blood glucose level and neuropathic pain in streptozotocin-induced diabetic rats. *African Journal of Pharmacy and Pharmacology*, 3: 636-642, (2009).



***Address for the Correspondence:**

Sukhvir kaur*

Rayat institute of pharmacy,

Railmajra (Ropar), Punjab

Contact no. 09779653788

Email: sukhvirdhanoa88@gmail.com